Company Description
908 Devices Inc., a commercial-stage technology company.
The company provides various purpose-built handheld and desktop mass spectrometry devices to interrogate unknown and invisible materials in life sciences research, bioprocessing, pharma/biopharma, forensics, and adjacent markets.
It also provides include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of solid, liquid, vapor, and aerosol materials of unknown identity; Rebel, a small desktop analyzer that provides real-time information on the extracellular environment in bioprocesses; and Maverick, an optical in-line analyzer that offers real-time monitoring and control of multiple bioprocess parameters, including glucose, lactate, and total biomass in mammalian cell cultures, as well as provides process fingerprint data to support large-scale efforts in predictive bioprocess modeling.
Its products also comprise Maven and Trace C2, an online device for bioprocess monitoring and control; and ZipChip solution, a plug-and-play, high-resolution separation platform that optimizes Mass Spec sample analysis.
The company operates in the United States, Europe, the Middle East, Africa, the Asia Pacific, and rest of the Americas.
908 Devices Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.
| Country | United States |
| Founded | 2012 |
| IPO Date | Dec 18, 2020 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 246 |
| CEO | Kevin Knopp |
Contact Details
Address: 645 Summer Street Boston, Massachusetts 02210 United States | |
| Phone | 857 254 1500 |
| Website | 908devices.com |
Stock Details
| Ticker Symbol | MASS |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $20.00 |
| CIK Code | 0001555279 |
| CUSIP Number | 65443P102 |
| ISIN Number | US65443P1021 |
| Employer ID | 45-4524096 |
| SIC Code | 3829 |
Key Executives
| Name | Position |
|---|---|
| Dr. Kevin J. Knopp Ph.D. | Co-Founder, Chief Executive Officer, President and Director |
| Joseph H. Griffith IV | Chief Financial Officer and Treasurer |
| Michael S. Turner Esq., J.D. | Chief Legal and Administrative Officer and Secretary |
| Dr. Christopher David Brown Ph.D. | Co-Founder and Advisor |
| Barbara Russo | Vice President of Marketing and Corporate Communications |
| Don Osmer | Vice President of Human Resources |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 7, 2025 | 8-K/A | [Amend] Current report |
| Mar 7, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 7, 2025 | 10-K | Annual Report |
| Mar 4, 2025 | 8-K | Current Report |
| Mar 4, 2025 | 8-K | Current Report |
| Feb 14, 2025 | SCHEDULE 13G/A | Filing |
| Jan 30, 2025 | SCHEDULE 13G/A | Filing |
| Jan 10, 2025 | SCHEDULE 13G/A | Filing |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |